Prevention of stroke in intracerebral hemorrhage survivors with atrial fibrillation (PRESTIGE-AF)
Funded by the European Commission, the PRESTIGE-AF project has been set up to help prevent further stroke in patients with existing conditions.
The project is aimed at patients who have had a stroke caused by bleeding in the brain (termed intracerebral haemorrhage or ICH), who also have atrial fibrillation (AF), a common heart condition which causes irregular and abnormally fast heartbeat and increases the risk of a stroke caused by a blood clot (termed an ischemic stroke)..
The research brings together scientists and clinicians across Europe with the goal of reducing the risk of further stroke in this group of patients.
Stroke is one of the largest public health challenges, and occurs when the blood supply to the brain is interrupted, such as through a clot or a brain bleed. It is the most common cause of adult-acquired disability, the second leading cause of death globally and the second most frequent cause of dementia. In addition, its impact is expected to further increase in the coming decades due to the ageing population.
At the core of the PRESTIGE-AF project is a clinical trial to gather evidence around recommended medication for stroke prevention in ICH patients with AF. Several sub-studies will explore individual predictive risk modelling using brain imaging, genetic testing and other biological markers. Other aspects of the project will include exploring cognitive and psychological factors and drug adherence by patients.
Launched in 2017, the project is led by Professor Roland Veltkamp from the Department of Medicine at Imperial College London and involves 11 other partner institutions throughout the UK and across Europe. Professor Veltkamp said: “Prevention of stroke is challenging in vulnerable stroke patients with multiple disorders and interacting risks. It’s this complexity that makes it difficult to work out the best individual preventive strategy for a particular patient. Working with our international partners through the PRESTIGE-AF initiative we hope to tackle some of the unmet needs of these patients and develop more personalised treatments. Prevention is key, and ultimately we aim to prevent stroke and the impact it has on patients’ lives.”
SAFE is responsible for disseminating information about PRESTIGE-AF to the stroke community. For more information, please contact email@example.com.
PRESTIGE-AF has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754517.
You can find more information on their website here: https://www.prestige-af.org/